γ-Aminobutyric acid (GABA) is a crucial inhibitory neurotransmitter with recognized benefits in alleviating depression. However, the ability of exogenous GABA to cross the blood-brain barrier remains debated, and the underlying anti-depression mechanismsthe "microbiota-brain" axis remain unclear. Herein, a high GABA-producing strain (ZFM559) was optimizedwhole-cell catalysis, and its derived GABA (pGABA, purity of 99.47%) was also prepared, followed by uncovering the underlying anti-depression mechanisms using a chronic unpredictable mild stress (CUMS) model. Results indicated that the administration of bothZFM559 and pGABA effectively alleviated depression-like behaviors and physiological disturbances, specifically manifested as suppressed hypothalamic-pituitary-adrenal (HPA) axis hyperactivity, relieved inflammation, and regulated serotonergic (5-HT) metabolism. These effects might be attributed to their ability to reshape the gut microbiota, notably increasing the abundance ofand, stimulating enterocytes to release 5-HTP. The circulating 5-HTP entered the brain, enhanced brainstem 5-HT synthesis, and subsequently upregulated the expression of CREB and pCREB while reducing the BDNF level. Notably,ZFM559 exhibited stronger effects than pGABA, likely due to its superior impact on tryptophan metabolism (non-kynurenine pathway) and microbial modulation (indole pathway). Our study highlights the potential of GABA-rich probiotics and their derived GABA as psychobiotics, offering a promising strategy for the dietary intervention of depressionthe microbiota-gut-brain axis. via L. lactis via L. lactis Akkermansia Ligilactobacillus L. lactis via